CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
NCT00558896
Completed
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone and CC-4047 may stop the growth of cancer cells by blocking blood flow to the cancer. Giving CC-4047 together with dexamethasone may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving CC-4047 together with dexamethasone works in treating patients with relapsed or refractory multiple myeloma or amyloidosis.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/20/2018
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Peri-Operative Steroid Management in Patients
NCT02084134
Completed
During transsphenoidal resection of pituitary tumors and cysts, surgery is performed by a neurosurgeon and ear nose and throat surgeon. The pituitary tumor or cyst is reached by making a small hole in the back of the nose into the bottom of the skull. The surgeon is able to see the pituitary and tumor with an endoscope and remove the tumor through the hole. Surgery on the pituitary can cause disruption in the secretion of ACTH and cause adrenal failure (lack of cortisol secretion) which can cau... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2018
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Pituitary Adenoma, Pituitary Diseases
Register for Updates
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
NCT01217957
Completed
The purpose of Phase 1 of this study was to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral ixazomib administered in combination with lenalidomide and low-dose dexamethasone in participants with newly diagnosed multiple myeloma (NDMM). The purpose of Phase 2 of this study was to determine the overall response rate (ORR) and further evaluate the tolerability and toxicity of the combination of oral ixazomib, lenalidomide, and low-dose d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2018
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +15 locations
Conditions: Multiple Myeloma
Register for Updates
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
NCT01983449
Completed
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries. Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2018
Locations: Arizona Heart Hospital / Abrazo Health Care Research / Tenet Health, Phoenix, Arizona +37 locations
Conditions: Peripheral Arterial Diseases
Register for Updates
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
NCT01651039
Completed
The purpose of this clinical research study is to find out the effects of a drug called panobinostat (LBH589) when given to people like you with multiple myeloma in combination with the drugs lenalidomide and dexamethasone. The safety of this combination of drugs will also be studied. Your physical state, changes in the state of your multiple myeloma, and laboratory findings taken while on-study will help us decide if panobinostat combined with dexamethasone and lenalidomide is safe and effectiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2018
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
NCT01231633
Completed
The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2018
Locations: Retina Vitreous Center, Toms River, New Jersey +3 locations
Conditions: Macular Edema, Central Retinal Vein Occlusion
Register for Updates
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
NCT01792102
Unknown
This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib for patients with progressive multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2018
Locations: James R. Berenson M.D. Inc., West Hollywood, California +1 locations
Conditions: Multiple Myeloma
Register for Updates
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
NCT00375791
Completed
This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2018
Locations: Investigative Site, Berkeley, California +6 locations
Conditions: Multiple Myeloma
Register for Updates
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
NCT02223598
Terminated
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2018
Locations: City of Hope National Medical Center, Duarte, California +7 locations
Conditions: Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
Register for Updates
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
NCT01698281
Terminated
This is a therapeutic exploratory Phase 2 study evaluating AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival (PFS) in patients with chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/20/2018
Locations: University of Miami, Miami, Florida +2 locations
Conditions: Breast Cancer
Register for Updates
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
NCT01488279
Completed
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2018
Locations: University of Vermont Clinical Research Center, South Burlington, Vermont
Conditions: Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Register for Updates
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
NCT01002248
Terminated
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2018
Locations: Not set, La Verne, California +87 locations
Conditions: Multiple Myeloma
Register for Updates